Connect Komodo, Optum, IQVIA, Flatiron, Truveta, and TriNetX. AI extracts patient journeys, prescribing patterns, payer dynamics, line-of-therapy progression, and switching behavior — synthesized into commercial and medical insights ready for executive decisions.
Connect, link, and normalize across the leading real-world data sources. Auto-deduplicate patients across sources for the largest possible cohort.
Patients are matched across sources using HIPAA-safe tokenization (Datavant, Privacy Hub) to maximize cohort size while preventing double-counting.
| Privacy Control | Implementation | Status |
|---|---|---|
| HIPAA Safe Harbor de-identification | All 18 identifiers removed before analysis | ✓ Verified |
| Expert Determination Method | Statistical certification by qualified expert (Datavant) | ✓ Verified |
| Tokenization for cross-source linkage | Privacy-preserving record linkage (PPRL) tokens | ✓ Verified |
| Small cell suppression | Cohorts <11 patients suppressed in outputs | ✓ Verified |
| Audit trail | Every query logged with user, timestamp, output | ✓ Verified |
| Data Use Agreements | All 6 source DUAs current and signed | ✓ Current |
Build patient cohorts with drag-and-drop logic. ICD-10, HCPCS, NDC, lab values, dates — all addressable without writing SQL.
Active cohort: 2L+ NSCLC Real-World Cohort (Q3 2026)
Trace patient pathways from diagnosis through multiple treatment lines. Identify drop-off points, treatment durations, and progression patterns.
| Pathway | 1L → 2L → 3L | Patient Count | Median Duration | % of Cohort |
|---|---|---|---|---|
| 1 | Pembrolizumab+Chemo → Docetaxel → Ramucirumab+Docetaxel | 42,389 | 14.2 mo | 8.7% |
| 2 | Pembrolizumab+Chemo → Atezolizumab → Docetaxel | 28,648 | 11.8 mo | 5.9% |
| 3 | Pembrolizumab → Docetaxel → Ramucirumab+Docetaxel | 24,872 | 13.4 mo | 5.1% |
| 4 | Carboplatin+Pemetrexed → Pembrolizumab → Docetaxel | 21,940 | 12.1 mo | 4.5% |
| 5 | Osimertinib (EGFR) → Carboplatin+Pemetrexed → Docetaxel | 18,124 | 22.8 mo | 3.7% |
| 6 | Pembrolizumab+Chemo → Nivolumab+Ipilimumab → Docetaxel | 14,387 | 13.6 mo | 3.0% |
| 7 | Atezolizumab+Chemo → Docetaxel → Ramucirumab | 12,196 | 10.4 mo | 2.5% |
| 8 | Pembrolizumab → Carboplatin+Paclitaxel → Docetaxel | 9,743 | 11.1 mo | 2.0% |
| 9 | Osimertinib → Carboplatin+Pemetrexed → Pembrolizumab | 7,860 | 19.4 mo | 1.6% |
| 10 | Alectinib (ALK) → Brigatinib → Lorlatinib | 5,432 | 28.6 mo | 1.1% |
Provider-level prescribing patterns, switch dynamics, and physician segment analysis. Identifies which prescribers drive volume and how to influence them.
| Segment | Count | Volume Share | Avg Patients/Mo | 2L Switch Rate | Key Driver |
|---|---|---|---|---|---|
| Academic NCI Cancer Centers | 218 | 14.2% | 42 | 68% | Trial enrollment + biomarker-driven |
| Large Community Practice (10+ MD) | 684 | 28.4% | 18 | 54% | Pathway adherence + payer policy |
| Mid Community Practice (3-9 MD) | 1,542 | 24.6% | 8 | 48% | Sales force + peer referral |
| Solo Practice | 2,406 | 12.8% | 3 | 38% | Local KOL + medical education |
| Integrated Health System | 486 | 15.4% | 28 | 62% | System-level pathway + P&T |
| VA / Federal | 156 | 4.6% | 14 | 42% | Federal formulary policy |
Payer-level prescribing patterns, prior authorization analytics, gross-to-net economics, and IRA exposure modeling.
| Payer | Volume Share | WAC ($/mo) | Allowed Amount | Effective Net | GtN% | PA Approval Rate | Days to Approval |
|---|---|---|---|---|---|---|---|
| UnitedHealthcare | 14.2% | $18,400 | $15,392 | $11,408 | 38% | 86% | 4.2 |
| Anthem (Elevance) | 13.8% | $18,400 | $14,392 | $10,672 | 42% | 82% | 5.8 |
| Aetna (CVS) | 11.2% | $18,400 | $14,024 | $10,304 | 44% | 78% | 6.4 |
| Cigna | 5.4% | $18,400 | $15,024 | $11,040 | 40% | 81% | 5.1 |
| Humana | 6.6% | $18,400 | $13,392 | $9,936 | 46% | 74% | 8.2 |
| Medicare Part B | 18.8% | $18,400 | $16,752 | $14,352 | 22% | 94% | 1.4 |
| Medicare Advantage | 12.4% | $18,400 | $14,896 | $11,408 | 38% | 80% | 4.8 |
| Medicaid (Managed) | 8.6% | $18,400 | $11,392 | $8,096 | 56% | 62% | 9.8 |
| BCBS Federal | 3.4% | $18,400 | $14,656 | $11,776 | 36% | 84% | 4.6 |
| Tricare/Federal | 2.6% | $18,400 | $15,584 | $13,248 | 28% | 92% | 2.1 |
One-click executive brief synthesizing all claims intelligence into commercial and medical strategic recommendations.
Analysis of 487,234 real-world 2L+ NSCLC patients across Komodo, IQVIA PharMetrics, Optum, and Flatiron reveals 5 strategic insights for commercial and medical leadership: (1) Docetaxel monotherapy dominates 2L creating clear whitespace for new 2L IO; (2) Top 1.9% of prescribers drive 42.6% of volume enabling focused field force investment; (3) Medicaid PA delays represent the largest access barrier; (4) EGFR+ patients have 22.8-month median 1L duration creating timed engagement opportunity for 2L; (5) IRA modeled NPV erosion of $890M-1.4B for Medicare-exposed therapies.
Finding: Docetaxel monotherapy accounts for 38% of 2L NSCLC therapy — a 25-year-old chemotherapy with significant toxicity (24% discontinuation rate due to AEs in real-world setting).
Implication: The dominant 2L therapy has well-documented tolerability issues but no superior alternative has displaced it because of cost and access barriers.
Recommendation: New 2L IO entrants should position around "better tolerability + meaningful efficacy" rather than "best-in-class efficacy alone." Real-world 2L treatment duration of 5.4 months suggests addressable market of $4.2B at peak penetration of 35%.
Finding: Top 902 prescribers (1.9% of universe) drive 42.6% of 2L NSCLC volume. These are concentrated in NCI Cancer Centers and large community practices.
Implication: Traditional broad-coverage rep model is wasteful. A focused specialty team of 20 reps can cover 80%+ of these prescribers vs ~150 reps needed for traditional 80/20 coverage.
Recommendation: Build 20-FTE oncology specialty team focused on top 902. Pair with digital + peer-to-peer for next-tier 1,542 prescribers. Annual SG&A savings vs traditional model: $32-48M.
Finding: Medicaid Managed Care (8.6% volume) has 62% PA approval rate vs 80%+ commercial. Humana (6.6% volume) has 8.2-day approval delay vs 4-day commercial median.
Implication: Two distinct access barriers requiring different solutions — Medicaid criteria template work and Humana medical director engagement.
Recommendation: Q4 deliverables — (a) NCCN-aligned PA template for top 5 Medicaid Managed Care plans (Centene, Molina, CareSource, AmeriHealth, AvMed); (b) Humana medical director engagement with utilization data. Estimated volume recovery: 15-20% in target segments.
Finding: EGFR+ patients on 1L Osimertinib have median 22.8-month treatment duration — a long "engagement window" before 2L switch.
Implication: Patients can be identified, educated, and pre-positioned for 2L therapy 18+ months before they need it.
Recommendation: Launch EGFR-specific patient identification program with prescribers managing > 20 EGFR+ patients. Develop "post-osimertinib progression" educational content. Estimated EGFR 2L share gain: 8-12 percentage points.
Finding: Medicare Part B + Medicare Advantage represent 31.2% of 2L NSCLC volume. Small molecule therapies face IRA Maximum Fair Price negotiation 9 years post-approval.
Implication: Modeled NPV erosion under base IRA scenario (30% MFP cut): $890M-1.4B over 5 years post-negotiation.
Recommendation: (a) Build pre-negotiation evidence package now — real-world OS validation, comparative effectiveness vs SoC, value-based contract pilots; (b) Pursue value-based contracts with top 5 commercial payers to demonstrate confidence in efficacy; (c) Pre-emptive ICER submission for independent value assessment.